Collin Hovinga

Collin Hovinga

Company: Critical Path Institute

Job title: Vice President of Rare and Orphan Diseases


Panel Discussion: Striving for Consensus on the Level of Evidence Required for Approval 10:45 am

How can we best reconcile the variance in acceptable measures of ALSFRS-R decline across geographies to get drugs to patients faster? How does the level of evidence required for accelerated approval vary in familial vs sporadic ALS? When are expanded access programs deemed acceptable ahead of final study results? If there’s going to be a…Read more

day: Day Two Track B AM

Panel Discussion: Exploring Ongoing Research Efforts Globally in ALS: How Will Future Study Read-Outs Transform the ALS Landscape? 3:40 pm

How are different research consortia implementing the Act for ALS, and what advancements are anticipated as a result? From expanded access programs to natural history studies, in what ways might these investigations influence the trajectory of ALS drug development? What are the current leading research priorities aimed at uncovering effective interventions for diagnosing, treating, managing,…Read more

day: Day Two PM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.